Search

Lost in translation

The article that follows is a collection of reflections and observations by Peter (British) and Nathan (Singaporean) living and working in each other’s countries. Peter Cackett “Best thing about this place is it’s not still full of pompous ex-colonials who...

The ‘theatre of the mind’: Charles Bonnet Syndrome and Esme’s Umbrella

The founder of Esme’s Umbrella shares her experience with the poorly understood condition Charles Bonnet Syndrome and the creation of the campaign. Many years ago, when I was a young actress, I was in an American play called ‘Butterflies are...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

Gene therapy for inherited retinal disease: the Manchester Ocular Gene Therapy Group MDT service

The authors describe the process set up in Manchester for the optimum delivery and assessment of a new gene therapy treatment for patients with RPE65 IRD. Inherited retinal dystrophies (IRDs) are the second commonest cause of severe visual impairment in...

Nano-ophthalmology paves a new path in the future of eyecare

Introduction The treatments of ocular conditions in the field of ophthalmology varies from topical to surgical procedures. The field of nanotechnology is one of the fast-growing fields of medicine, which plays an important role in turning the impossibilities of the...

Treatment of diabetic macular oedema

Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...